年龄、性别、治疗意图、种族及晚期心衰严重程度对MOMENTUM 3试验短期主要结局的影响
基于MOMENTUM 3试验289例按治疗分析队列,Cox模型显示年龄≤65岁(HR 0.42,95%CI 0.22–0.78,P=0.006)和HM3泵(HR 0.53,95%CI 0.30–0.96,P=0.034)是主要终点成功的独立预测因素,校正年龄后性别、种族、治疗意图及INTERMACS分级无显著影响。作者认为治疗意图的桥接与终点治疗分类无明确临床优势,应放弃。
要点
- 年龄≤65岁与主要终点成功独立相关(HR 0.42,95%CI 0.22–0.78,P=0.006)。
- HM3较HMII与主要终点成功独立相关(HR 0.53,95%CI 0.30–0.96,P=0.034)。
- 校正年龄后性别、种族、治疗意图及INTERMACS分级对主要终点无显著影响。
核心结论
- MOMENTUM 3分析提示植入时较年轻(≤65岁)和泵选择与主要终点成功可能性更高相关。
- 作者认为将治疗意图细分为桥接至移植和终点治疗类别无明确临床优势,理想情况下应放弃。
研究设计与样本
- MOMENTUM 3试验按治疗分析队列(n=289)的Cox比例风险模型分析。
- HM3组n=151,HMII组n=138,基线特征均衡。
主要发现
- 各亚组对主要终点结局无显著交互作用。
- 年龄≤65岁 vs >65岁:HR 0.42(95%CI 0.22–0.78),P=0.006。
- HM3 vs HMII:HR 0.53(95%CI 0.30–0.96),P=0.034。
- 校正年龄后,性别、种族、治疗意图和INTERMACS分级对主要结局无显著影响。
临床怎么用
- 作者认为治疗意图的桥接至移植与终点治疗分类无明确临床优势,理想情况下应放弃。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary outcomes analysis of the Multicenter Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3 (MOMENTUM 3) trial short-term cohort demonstrated a higher survival rate free of debilitating stroke and reoperation to replace/remove the device (primary end-point) in patients receiving the HeartMate 3 (HM3) compared with the HeartMate (HMII). In this study we sought to evaluate the individual and interactive effects of pre-specified patient subgroups (age, sex, race, therapeutic intent [bridge to transplant/bridge to candidacy/destination therapy] and severity of illness) on primary end-point outcomes in MOMENTUM 3 patients implanted with HM3 and HMII devices. METHODS: Cox proportional hazard models were used to analyze patients enrolled in the "as-treated cohort" (n = 289) of the MOMENTUM 3 trial to: (1) determine interaction of various subgroups on primary end-point outcomes; and (2) identify independent variables associated with primary end-point success. RESULTS: Baseline characteristics were well balanced among HM3 (n = 151) and HMII (n = 138) cohorts. No significant interaction between the sub-groups on primary end-point outcomes was observed. Cox multivariable modeling identified age (≤65 years vs >65 years, hazard ratio 0.42 [95% confidence interval 0.22 to 0.78], p = 0.006]) and pump type (HM3 vs HMII, hazard ratio 0.53 [95% confidence interval 0.30 to 0.96], p = 0.034) to be independent predictors of primary outcomes success. After adjusting for age, no significant impact of sex, race, therapeutic intent and INTERMACS profiles on primary outcomes were observed. CONCLUSIONS: This analysis of MOMENTUM 3 suggests that younger age (≤65 years) at implant and pump choice are associated with a greater likelihood of primary end-point success. These findings further suggest that characterization of therapeutic intent into discrete bridge-to-transplant and destination therapy categories offers no clear clinical advantage, and should ideally be abandoned.
引用
- Goldstein DJ, Mehra MR, Naka Y, et al. Impact of age, sex, therapeutic intent, race and severity of advanced heart failure on short-term principal outcomes in the MOMENTUM 3 trial. J Heart Lung Transplant. 2017. PMID: 29154131. doi:10.1016/j.healun.2017.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。